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ABSTRACT
PURPOSE: To review the peer-reviewed literature re-
porting postoperative complications of the most recent 
models of Visian Implantable Collamer posterior cham-
ber intraocular lenses (ICL, STAAR Surgical Co).
METHODS: A literature search of the PubMed database 
was performed to identify all articles related to ICL com-
plications. Articles were obtained and reviewed to iden-
tify those that reported complications using the latest 
ICL designs.
RESULTS: Cataract was the major postoperative com-
plication reported: 136 (5.2%) in 2592 eyes. Of those, 
43.4% (n=59) were reported within 1 year, 15.4% 
(n=21) between 1 and 3 years, and 35.3% (n=48) >3 
years after ICL implantation. Twenty-one (15.4%) cata-
racts were reported as surgically induced, 46 (33.8%) 
eyes had poor vault (,200 µm), and cataract surgery 
was carried out in 27.9% (n=38) of eyes. Early acute 
intraocular pressure increase was also reported to be 
relatively frequent, whereas acute pupillary block was 
less frequent and mostly resolved with additional iridoto-
mies. A total of 42 ICLs were explanted due to cataract 
and IOP. Reported endothelial cell loss varied from 9.9% 
at 2 years to 3.7% 4 years postoperatively. This loss was 
reported to be more pronounced within the fi rst 1 to 2 
years, with stability or lower progression after that time.
CONCLUSIONS: The majority of reported complica-
tions after ICL implantation are cataract formation. The 
improvements in lens geometry and more accurate 
nomograms applied to the selection of the lens to be 
implanted, in addition to the surgeon’s learning curve, 
might be factors in the decreased occurrence of postop-
erative complications reported currently. [J Refract Surg. 
2011;xx(x):xxx-xxx.] 
doi:10.3928/1081597X-20110617-01
C
urrently, phakic intraocular lenses (PIOLs) are gen-
erally accepted as an  alternative treatment for am-
etropia correction among various refractive ranges, 
and their implantation is an emerging technique within the 
fi eld of refractive surgery. Faster visual recovery, high effi -
cacy and stability of visual quality, preservation of accom-
modation, and reversibility are several advantages that have 
been attributed to PIOL implantation.1,2 
The Visian Implantable Collamer Lens (ICL; STAAR Surgi-
cal Co, Monrovia, California) is the only posterior PIOL that 
is currently approved by the United States Food and Drug 
Administration (FDA) for the treatment of moderate to severe 
myopia.1 It is a foldable PIOL consisting of a plate-haptic de-
sign with a central convex/concave optical zone and a for-
ward vault to minimize contact with the crystalline lens. After 
the fi rst prototypes were implanted several models followed, 
with major changes occurring in the built-in vault height to 
warrant consistent clearance from the crystalline lens and 
have reduced previous problems due to inadequate vaulting. 
Several published studies have confi rmed ICL implantation 
as a feasible treatment to correct myopia,2-4 hyperopia,5-7 or 
astigmatism,8-13 with clinical and visual results as good as or 
better than laser procedures.14-16 Patients who are not suitable 
candidates for corneal reshaping procedures, and in whom 
optical correction with spectacles or contact lenses is either 
challenging or renders poor results,9,17-22 can benefi t from this 
surgical solution.
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Although the published studies reporting results of 
ICL implantation have low rates of adverse events, car-
rying out a comparative analysis of the occurrence, type, 
and visual outcomes of postoperative complications has 
proven diffi cult and variable,23 as the majority of pub-
lished studies include different versions of earlier models 
of ICLs. To provide an updated view of current potential 
threats of ICL implantation, the present article provides 
results and conclusions derived from published, peer-
reviewed studies reporting the outcomes and potential 
complications of the latest Visian ICL models. 
ICL MODELS AND LITERATURE REVIEW
CLINICAL STUDIES REPORTING POSTOPERATIVE 
COMPLICATIONS AFTER VISIAN ICL IMPLANTATION 
A Medline search from January 1999 to May 2010 
was performed to identify all journal articles related 
to posterior PIOLs. The terms posterior PIOL, Implant-
able Collamer Lens, Implantable Contact Lens, and 
ICL were used for a wide and sensitive search. Other 
searches were performed to identify additional articles 
that were pertinent to clinical results or ICL compli-
cations using terms such as complications of PIOLs, 
vault, anterior subcapsular cataract, pigment disper-
sion, intraocular pressure (IOP), endothelial loss, cata-
ract extraction, angle narrowing, endophthalmitis, and 
retinal detachment. 
Copies of the articles were obtained and reviewed to 
identify those that reported original clinical data or com-
plications after ICL implantation. Furthermore, their 
reference lists were searched manually for additional 
articles published in peer-reviewed journals. Only jour-
nal articles published in English were included. Only 
those articles using the latest designs of Visian ICL (V4 
for myopia and astigmatism and V3 for hyperopia) were 
included. Articles reporting complications after ICL 
implantation in which the exact numbers of eyes being 
affected were unknown or the ICL model was not re-
ported were excluded. Particular attention was given to 
avoid duplication of data of published papers covering 
previously published cases; only those adding new cases 
were included. Of those papers including different and 
earlier versions of the Visian ICL, only those cases im-
planted with the latest version of the lens were included. 
The signifi cant complications reported regarding safety, 
such as anterior subcapsular cataract formation, in-
creased IOP, endothelial cell loss, and any other clini-
cal complications represent the outcomes of interest for 
this review. 
VISIAN ICL MODELS
The Visian ICL is a foldable PIOL made from a bio-
compatible material named Collamer, composed of a 
hydrophilic porcine collagen (,0.1%)/hydroxyethyl 
methacrylate copolymer with an ultraviolet-absorbing 
chromophore. It features a plate-haptic design with a cen-
tral convex/concave optical zone and incorporates a for-
ward vault to minimize contact of the ICL with the central 
anterior capsule of crystalline lens. This lens was designed 
to be placed in the posterior chamber behind the iris with 
the haptic zone resting on the ciliary sulcus. 
Figure 1. Top) Front and side view of the 
different Implantable Collamer Lens (ICL; 
STAAR Surgical Co) models for myopia 
(ICMV4), hyperopia (ICHV3), and astigma-
tism (TICMV4). Bottom) Change in vault 
of the ICMV4 lens compared to the ICMV3 
model. Note: The ICHV3 model has the 
same vault as the ICMV4 model. 
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After the fi rst prototypes were implanted, some simi-
lar models followed with slight modifi cations, mainly 
in the built-in vault height. The latest Visian ICL models 
are the ICMV4 for myopia, ICHV3 for hyperopia, and 
TICMV4 for myopic astigmatism. The ICL is a rectan-
gular, 7-mm-wide lens implant, available in four over-
all lengths (11.5, 12, 12.5, and 13 mm for the myopic 
and toric lenses, so called ICM and TICM, respectively; 
and 11, 11.5, 12, and 12.5 mm for the hyperopic lenses, 
so called ICH). The optic diameter ranges from 4.65 
to 5.5 mm in the ICM and TICM models, depending 
on the dioptric power, being always 5.5 mm for ICH 
lenses. Front and side views of the Visian ICL V4 for 
myopia, hyperopia, and astigmatism are shown in Fig-
ure 1 (top) along with a comparison between the vault 
of the Visian V3 and Visian V4 for myopia (see Fig 1, 
bottom). In an attempt to increase the clearance from 
the anterior crystalline lens surface, and therefore min-
imize the risk of iatrogenic subcapsular anterior opaci-
ties, the V4 has an additional 0.13 to 0.21 mm of anterior 
vault height due to the steeper radius of curvature of 
the base curve and dioptric power (see Fig 1). When 
appropriately selected, the lens creates a clearance 
space over the whole anterior crystalline lens surface. 
LITERATURE REVIEW RESULTS
An initial literature search identifi ed 108 articles 
reporting the results of ICL implantation to correct dif-
ferent degrees of myopia, hyperopia, and astigmatism, 
among other applications. Based on the defi ned crite-
ria, 44 articles were included in the present review.
Following the criteria previously quoted, and after 
a careful and systematic review of the complete arti-
cles, the postoperative complications and their treat-
ment were obtained. The major postoperative compli-
cations documented for these lenses were crystalline 
lens opacities, increased IOP and pupillary block, and 
endothelial cell loss. The occurrence of cataract for-
mation was determined as a percentage of the sum of 
cataract events reported over the total number of ICLs 
implanted. The percentages of complications given 
herein are not values of incidence on the general popu-
lation undergoing these procedures. Instead, these re-
fl ect the percentage of cases reported over the whole 
sample analyzed in the articles surveyed.  
CRYSTALLINE LENS OPACITY
Table 1 shows a summary of studies reporting cata-
ract development after implantation with the latest 
ICL models.7,10,13,16,24-37 Data from 13 articles reporting 
cataract development after implantation of ICMV4 for 
myopia,13,25-35 3 reports on ICHV3 for hyperopia,7,25,28 
and 4 reports on TICM for astigmatism10,13,16,37 are pre-
sented, comprising a total of 2592 eyes surveyed. Of 
those eyes, 2142 (82.6%) were implanted with the 
ICMV4, 112 (4.3%) with the ICHV3, and 338 (13.0%) 
with the TICMV4. A total of 136 (5.2%) eyes have been 
reported with cataract, and the occurrence varied with-
in a range from 1.3%31 to 28%35 in the ICM group, 6%7 
to 14.3%28 in the ICH group, and 2.3%16 to 10.4%13 in 
the TICM group. The majority of ICL-associated cata-
racts were reported as being anterior subcapsular. For 
those reporting the time of onset, the average time for 
the development of cataract after ICL implantation var-
ied from 1256116 days (range: 1 week to 14 months)22 
to 44631 months (range: 7 to 120 months).35 Of those 
eyes developing cataract for which the approximate 
time of onset was known, 43.4% (n=59) were reported 
within 1 year, 15.4% (n=21) between 1 and 3 years, and 
35.3% (n=48) >3 years after ICL implantation (Fig 2). 
For the remaining eyes (n=8), the time of onset could 
not be accurately determined. 
Early crystalline lens opacities (.40%) were reported 
to be possibly related with surgical trauma or ICL–crys-
talline contact, as they directly involved the anterior cap-
sule as suggested by the authors of the articles surveyed. 
In the present analysis, 21 (15.4%) eyes with cataract 
were reported as surgically induced, mostly associated 
to inadvertent lens touch during ICL insertion or other 
intraoperative complications. Lackner et al26 reported 4 
eyes developing cataract due to a prolonged surgery in 
elderly patients with a shallow anterior chamber and 
narrow pupil. Sanders30 reported 1 patient develop-
ing cataract after vitreoretinal manipulation. Sanchez-
Galeana et al25 observed that most of the early-onset cat-
aracts occurring in the immediate postoperative period 
Figure 2. Time of onset (years), potential causes (surgically induced, poor 
vault, age, and high ametropia), and clinical outcomes (clinically significant 
cataract and phacoemulsification) of anterior subcapsular cataract after 
ICL implantation. Clinically insignificant cataracts are not reported. 
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(up to 3 months) were frequently asymptomatic and 
associated with surgical trauma. Surgeon learning curve 
has also been reported by those authors as a risk factor 
for the early development of cataract.25 This has been 
supported by their fi ndings, in which 79% (11/14) of 
opacities occurred in the fi rst or second implantation of 
surgeons-in-training, and with increased surgical expe-
rience the incidence of opacities dropped from 19% to 
0% for the same surgeon.25 Sanders et al,38 in a multi-
center trial, found that the incidence of lens opacities 
increased with inexperienced surgeons and 2 of 19 sur-
geons in their study were responsible for the majority of 
observed lens opacities. 
Regarding cataract development 1 year after ICL 
implantation, several factors have been reported. 
Patient-dependent factors at the time of ICL implan-
tation, such as age and preoperative refractive status, 
were considered predictive risk factors for cataract de-
velopment after ICL implantation by several studies. 
Gonvers et al39 reported higher incidence of cataract 
development in older patients (14% of young patients 
[age: 10 to 40 years] versus 37% of older patients [age: 
41 to 50 years]). Lackner et al26 reported in a series of 
76 eyes that all eyes with late cataract development 
(n=11) were in patients older than 50 years. In a study 
by Alfonso et al,31 in 1.3% of eyes (13/964) develop-
ing cataract after ICL implantation, patient age was 
the parameter with the highest correlation with cata-
TABLE 1
Studies Reporting Incidence of Anterior Subcapsular Cataract After 
Implantable Collamer Lens (ICL) Implantation
Study Lens Type No. Eyes Age (Range) (y) SE (Range) (D)
Gonvers et al24 ICM 13 39.969 (22 to 50) 214.8765.89 (26.78 to 228.25)
Sanchez-Galeana et al25 ICM 96 37.168.4 (21 to 60) —
Lackner et al26 ICM 76 48.367.4 (21 to 59) 216.565.60 (25.50 to 233.40)
Sarikkola et al27 ICM 26 34 (24 to 42) 215.1064.59 (26.75 to 223.50)
Bleckmann & Keuch28 ICM 99 42.7611.9 8.5664.30 (24.00 to 19.25)
Chang & Meau29 ICM 61 34.9 214.5463.61 (27.00 to 224.75)
Sanders30 ICM 526 36.565.9 (22 to 45) 210.0663.74 (23.00 to 220.00)
Alfonso et al31 ICM 964 32.5066.05 (18 to 53) 29.4764.12 (23.25 to 224.00)
Chung et al32 ICM 49 34.369.5 (21 to 49) 214.0064.00 (26.25 to 223.25)
Kamiya et al33 ICM 56 37610.3 (21 to 59) 29.8363.00 (24.00 to 215.25)
Boxer Wachler et al34 ICM 30 39.6 (25 to 56) 211.4863.84 (27.00 to 220.25)
Lindland et al13 ICM 48 36 (19 to 52) 29.10 (24.30 to 224.30)
Schmidinger et al35 ICM 98 36610 (10 to 46) 216.4065.40 (25.50 to 229.00)
Pesando et al7 ICH 50 38.4164.9 (31 to 55) 15.7862.54 (+2.50 to +11.75)
Sanchez-Galeana et al25 ICH 34 — —
Bleckmann & Keuch28 ICH 28 — +3.6261.72 (+2.75 to +7.75)
Sanders et al10 TICM 210 36.467.4 (21 to 45) 29.3662.66 (22.38 to 219.50) 
CYL 1.9360.84 (1.00 to 4.00)
Schallhorn et al16 TICM 43 30.866 28.0461.28 (26.00 to 220.00) 
CYL 1.7360.62 (1.00 to 4.00)
Lindland et al13 TICM 29 34.6 (25 to 48) 28.50 (23.50 to 217.50) 
CYL 2.50 (1.00 to 4.80)
Kamiya et al37 TICM 56 35.5 (23 to 50) 210.3762.78 (24.00 to 217.25)
CYL 2.15 (0.75 to 4.00)
Total 2592
SE = spherical equivalent refraction, ASC = anterior subcapsular cataract, ICM = ICL for myopia, ICH = ICL for hyperopia, TICM = ICL for astigmatism,
CYL = refractive cylinder
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ract development; additionally, those eyes tended to 
present lower vault values, average lower ICL size, and 
shallower anterior chamber depth. In a study by Sand-
ers,30 all clinically signifi cant cataracts occurred in the 
group with myopia .210.00 diopters (D). In the study 
by Sanchez-Galeana et al,25 mean spherical equivalent 
refraction in eyes with cataract was 219.2065.40 D 
versus 217.1064.70 D for those without cataract de-
velopment in the myopic group and 18.6061.20 D ver-
sus 16.2061.90 D for those with and without cataract 
development in the hyperopic group. Furthermore, all 
4 opacities in the hyperopic group occurred in eyes 
with a lens diameter of 11.0 mm, which is no longer 
produced by the manufacturer.
The separation between the ICL and crystalline lens 
is also an important issue associated with cataract for-
mation after ICL implantation. It has been suggested that 
insuffi cient vault might induce cataract formation by me-
chanical interaction or trauma on the anterior capsule.39 
Additionally, poor vault could also lead to disturbances 
in aqueous fl ow, interfering with lens nutrition and caus-
ing metabolic disturbances to the crystalline lens.1,40,41 In 
those reports in which data were available regarding vault 
values,7,13,16,24,28,31-34 46 (33.8%) eyes were documented to 
have poor vault (,200 µm). An underestimation in the 
selection of the ICL diameter was frequently associated 
with poor vault immediately after surgery and, in these 
cases, anterior subcapsular cataract was more likely to 
Onset (No. Eyes [%])
Follow-up (Range) (mo) Total ASC (%) Early (,1 y) 1 to 3 y Late (.3 y) Potential Etiology
7.462.8 (3 to 14) 1 (7.7) 1/13 — — Low vault
12.264.9 (8 to 27) 6 (6.3) 6/96 — — Surgically induced
24611.5 11 (14.5) 9/69 1/42 1/19 Age
13 2 (7.7) 2/26 — — Surgically induced
31618 5 (5.1) — — — —
13.6768.51 (1 to 32) 1 (1.6) — 1/17 — Surgically induced
60 31 (5.9) 18/428 5/468 8/384 High myopia; age
36 13 (1.3) 2/506 7/147 4/139 High myopia; age; 
low vault
33.267.3 (24 to 47) 2 (4.1) 2/48 — — Surgical trauma; low vault
48 8 (14.3) 2/56 6/56 — Surgical trauma; low vault
3 2 (6.7) 2/30 — — Surgical trauma; low vault
65 (11 to 84) 7 (14.6) 1/48 — 6/48 ICL–crystalline contact; 
low vault
74.1623.1 (26 to 124) 23 (28.0) — — 23/84 Low vault
46 (6 to 120) 3 (6.0) — — 3/6 Low vault
12 4 (11.7) 4/34 — — ICH size 11 mm
31618 4 (14.3) — — — Low vault
12 6 (2.9) 6/200 — — —
12 2 (2.3) 1/43 1/43 — Low vault
60 (10 to 76) 3 (10.4) — — 3/29 ICL–crystalline contact; 
low vault
12 3 (5.4) 3/56 — — —
136 (5.2) 58/1715 21/773 48/765
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occur due to ICL–crystalline lens contact. 
In the study by Gonvers et al,24 the one cataract ob-
served with the V4 model was associated with absence 
of vault (direct contact between ICL and crystalline 
lens). In a study conducted in myopic Asian eyes by 
Chang and Meau,29 the only cataract occurred in a case 
in which the lens was considered too small. Sarikkola 
et al27 reported that the appearance of cataract could 
fi rst be seen beneath the thickest part in the mid-
periphery of the ICL as a circle on the anterior crystal-
line lens surface in myopic eyes and in the central area 
in hyperopic eyes. This characteristic location of the 
cataract might be expected to affect patients with high-
er refractive errors due to the inherent geometry of the 
lenses. Moreover, a trend for vault to slightly decrease 
over time has been reported, which could lead to simi-
lar problems even if enough vault was warranted im-
mediately after surgery.31 Schmidinger et al35 reported 
a signifi cant and continuous reduction in central 
vaulting over a 10-year period in eyes treated with an 
ICMV4 model—eyes that developed cataract with this 
lens had midperipheral contact between the ICL and 
anterior crystalline lens surface. They also reported a 
mean vaulting of 2166104 µm at the initial manifesta-
tion of cataract and 986100 µm by the time of cataract 
removal. In the study by Boxer Wachler et al,34 of the 
two eyes that had trace cataract, one eye had no vault 
and the ICL was replaced by a larger diameter lens.
Studies that evaluated the pathophysiology of an-
terior subcapsular cataracts secondary to ICL confi rm 
those associations between cataract development and 
lower vault.28,42,43 In a study of 127 eyes by Bleckmann 
and Keuch,28 5 eyes that had vault ,150 µm developed 
cataract. Histological examination of anterior capsule 
fragments after phacoemulsifi cation revealed some evi-
dence that contact or closeness of the phakic lens to the 
crystalline capsule might have induced permeation dis-
turbances, which may have led to a cascade of metabolic 
disturbances and transformations within the epithelial 
cells. Using light microscopy, Khalifa et al42 evaluated 
the histopathology of anterior subcapsular cataract asso-
ciated with ICL in 4 eyes that had ICL explantation due 
to low vault and cataract surgery. The histopathology of 
the anterior subcapsular cataract showed fi brous meta-
plasia of the anterior subcapsular lens epithelial cells 
with dense fi brous tissue attached to the inner surface 
of the anterior capsulorrhexis specimens corresponding 
to the areas of anterior subcapsular cataract. In addi-
tion, light microscopy of the explanted ICL showed a 
varied amount of pigment deposition and locations, and 
the authors state that these histopathologic changes are 
thought to be due to disturbance of the aqueous fl ow, 
causing metabolic changes within the crystalline lens 
structure or intermittent microtrauma.42
Regarding clinical signifi cance of cataract, most 
were reported as nonprogressive or slowly progres-
sive and asymptomatic and were placed under surveil-
lance. However, in 30.1% (n=41) of eyes, the opacity 
became clinically signifi cant and cataract surgery was 
performed in 27.9% (n=38) of eyes. The duration of 
follow-up should also be taken into account given that 
the occurrence of cataract is higher in patients with 
longer follow-up.26,33,35
Combined PIOL explantation and cataract surgery 
was reported to be an easy and feasible procedure43 
once the lens was extracted through its original cor-
neal incision or at a site identical to the original inci-
sion with usually minimal trauma because of the lens’ 
fl exibility.44,45 All patients in studies published to 
date who underwent combined PIOL explantation and 
phacoemulsifi cation had successful reimplantation of 
pseudophakic IOLs and did not show any adverse effects 
derived from the combined procedure. Bleckmann and 
Keuch28 reported an improvement in corrected dis-
tance visual acuity (CDVA) after cataract surgery of 
1.4461.33 lines more than that before ICL implanta-
tion. Morales et al46 also reported that the mean CDVA 
before ICL implantation, after ICL implantation, and 
after cataract surgery was 0.3160.32, 0.2860.19, and 
0.2760.21 logMAR, respectively. Kamiya et al45 re-
ported an improvement of one line in CDVA in the 
only ICL V4–induced cataract observed in the study. 
In the study by Khalifa et al,42 the four eyes that under-
went ICL explantation and cataract surgery achieved 
CDVA of 20/20. With regard to the predictability of 
these combined procedures, it has been reported that 
they offer high predictability of the intended correc-
tion. Bleckmann and Keuch28 stated that refractive error 
did not exceed 1.00 D irrespective of the initial refraction 
or degree of hyperopia or myopia. Morales et al46 reported 
that the percentage of eyes within 61.00 D of the targeted 
correction was 71.4%. Kamiya et al45 reported that the 
percentages of eyes within 60.50 D and 61.00 D of the 
targeted correction 3 months after surgery were 80% 
and 90%, respectively. In addition, they also reported 
a high patient satisfaction rate with visual outcomes 
with the combined surgery. 
It is known that the presence of an IOL will affect 
axial length measurements. Recently, however, Sanders 
et al47 determined that the axial length measurements 
made by partial coherence laser interferometry are not 
signifi cantly affected by the presence of a phakic ICL. 
The maximum difference between pre- and postopera-
tive PIOL axial length measurements was less than 0.1 
mm, which will barely induce clinically signifi cant er-
rors near 0.25 D; even with axial lengths of 30 mm. 
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Morales et al46 also stated that the difference between 
the axial length measurements before ICL implantation 
and those after was small. These fi ndings may some-
what account for the higher predictability of these 
combined procedures.
INTRAOCULAR PRESSURE
Table 2 summarizes those studies reporting an in-
crease in IOP2,11,26,29,31,32,36,48-57 after implantation of the 
ICL V4 model and the procedures adopted to resolve 
it. An early rise in IOP was reported to be relatively 
frequent and usually moderate (,30 mmHg). Incom-
plete removal of viscoelastic material and instillation 
of steroid eye drops11,29,32 or the reduction of the angle 
opening distance (41.5%) and reduction of the trabecu-
lar-iris angle (31.8%)32 were associated with this rise, 
which was usually observed within the fi rst month af-
ter surgery. When asymptomatic and not followed by 
marked chamber shallowing, these situations often re-
solved spontaneously within the fi rst 48 hours and did 
not need any special treatment or resolved with tempo-
rary topical antiglaucoma medication.26,32 Chronic pig-
ment dispersion was also suggested as another potential 
cause of increased IOP58 and can be related to preopera-
tive laser iridotomies or chronic iris chafi ng by the ICL. 
Chung et al32 found that the mean trabecular meshwork 
pigmentation at 1 month postoperatively was not sig-
nifi cantly different from the preoperative value with the 
ICL V4 model, and the ongoing reduction observed dur-
ing postoperative follow-up may refl ect the progressive 
clearing of the pigment dispersion secondary to laser 
iridotomies. Sanchez-Galeana et al52 reported a patient 
who developed pigment glaucoma with refractory in-
crease in IOP; medical therapy and lens explantation 
trabeculectomy were performed to reduce IOP. Chung 
et al32 reported one eye showing increased IOP with 
signifi cantly increased trabecular pigmentation 1 week 
postoperatively, despite low ICL vaulting. Signifi cant 
pigment deposits were observed on the ICL surface and 
prolonged antiglaucoma medication was necessary.
In some cases, the rise in IOP remained persistent 
and a secondary emergency procedure was required. 
Acute pupillary block2,29,49,51 and subsequent narrow-
ing of the iridocorneal angle are considered primary 
causes of sustained elevated IOP, frequently associ-
ated with inadequate preoperative iridotomies2,49,51 
and/or excessive ICL vault (usually by an overestima-
tion of the ICL size31,36). Smallman et al49 reported bi-
lateral ICL explantation because of the risk for further 
episodes of pupillary block in a patient with delayed 
pupillary block glaucoma from closure of iridotomies. 
A similar complication was reported by Park et al.53 
The majority of cases with pupillary block are success-
fully managed by enlargement of existing iridotomies 
or by the creation of additional surgical peripheral iri-
dectomies,54,55 avoiding the need to explant the ICL. 
The use of cycloplegic agents was also reported to 
temporarily relieve IOP in this ICL-induced angle clo-
sure mechanism51,56 by reducing the inward compressive 
force on the ICL footplates and consequential ICL vault 
reduction and avoidance of angle closure. Nevertheless, 
in some cases, acute angle closure is secondary to nonpu-
pillary block mechanism,50,56,57 as described by Khalifa et 
al.57 This nonpupillary block mechanism is mainly due 
to an overestimation of ICL size and excessively vaulted 
ICLs, as a result of a poor correlation between white-to-
white distance and sulcus-to-sulcus diameter50,57 and/or 
to an abnormally large and irregular ciliary process.56 
These particular cases do not respond to additional laser 
or surgical iridotomies and ICL extraction is necessary. 
ENDOTHELIAL CELL LOSS
Table 3 presents a summary of studies reporting 
endothelial cell loss secondary to implantation of the 
latest versions of ICL.7,11,26,32,33,37,59-61 Some discrepan-
cies are present within the data. Some authors report-
ed that mean endothelial cell density was signifi cantly 
lower at 1 month after ICL implantation by 9.9%,32 and 
this decrease was maintained during the subsequent 
2 years. Pesando et al7 reported 4.7% cell loss at ap-
proximately 6 months, which remained unchanged 
throughout 10-year follow-up, whereas others reported 
6.1% cell loss after 3 years59 and 3.7% cell loss 4 years 
after ICL implantation.33 Alfonso et al19 reported cor-
neal endothelial cell loss of 8.1% 2 years after toric ICL 
implantation in eyes after penetrating keratoplasty. 
Coeffi cient of variation of endothelial cell size did not 
show a signifi cant change during the fi rst year after sur-
gery, but it was signifi cantly lower thereafter,32,61 where-
as mean percentage of hexagonality remained stable or 
slightly increased throughout the postoperative period. 
Despite this, in all studies, the rate of endothelial cell loss 
slowed down substantially from 1 to 2 years, and tended 
to remain stable or have lower progression after that 
period. Edelhauser et al61 reported a cumulative endo-
thelial cell loss of 8.4% and 8.5% over the fi rst 3 and 4 
years, respectively. This loss continued at a rate of 2% 
to 3% per year over the fi rst 3 years and a cell increase 
of 0.1% between 3 and 4 years of follow-up. From these 
fi ndings in cell loss behavior, the authors considered pro-
longed corneal remodeling following the surgical proce-
dure to be the cause of the early corneal endothelial cell 
loss61 whereas further decrease in cell density in the late 
postoperative period may be due to natural cell loss.62
ENDOPHTHALMITIS AND RETINAL DETACHMENT
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Implantation of a posterior chamber PIOL carries 
a potential risk for intraocular complications such as 
endophthalmitis and retinal detachment. Allan et al63 
conducted an anonymous online survey of 234 sur-
geons in 21 countries to determine how many of their 
ICL cases had been complicated by endophthalmitis 
between January 1998 and December 2006. During the 
study period, 95 (40%) surgeons responded to the sur-
vey with a total of 17 954 ICLs implanted and 3 sur-
geons reported 1 case of endophthalmitis each, a rate 
of 0.0167% or approximately 1 case of endophthalmi-
tis per 6000 ICL implantations. Davis et al64 reported 
a case of culture-positive bacterial endophthalmitis 4 
days following ICL implantation. The patient made a 
full visual recovery after proper treatment.
Most ICL implantations are performed in patients 
with high myopia and long axial length; therefore, 
these eyes have a predisposition for retinal detach-
ment.2,29,65 In the US FDA trial,2 3 retinal detachments 
were reported in 526 eyes. Retinal detachment was re-
ported in 1 eye 15 months after ICL implantation in a 
study comprising 61 eyes, and this case was attributed 
to the pre-existing axial length of 31.0 mm.29 In a retro-
spective study of 628 eyes implanted with the ICL V4, 
Martinez-Castillo et al65 reported retinal detachment 
in 11 eyes, which occurred from 1 to 70 months after 
lens surgery. The authors attributed these cases to pre-
existing high myopia and long axial length (.30 mm). 
DISCUSSION
Apart from the rare adverse risks of intraocular sur-
gery, mild endothelial cell loss, increased IOP and pu-
pillary block, and cataract formation are the most docu-
mented safety concerns related to ICL implantation. 
Although a number of articles in the peer-reviewed 
literature support the relatively low rate of complica-
tions after ICL implantation, development of anterior 
subcapsular opacities and clinically signifi cant cataract 
remain a major concern. In a recent meta-analysis by 
Chen et al,23 the incidence of cataract formation in the 
STAAR Collamer group (1933 eyes) was 8.48%. Early 
cataract formation was attributed to surgical trauma 
whereas late cataract formation was attributed to ICL–
crystalline lens contact. However, the meta-analysis 
considered all ICL designs, including earlier versions 
that are now discontinued. In the present literature re-
view comprising 2592 eyes, the occurrence of cataract 
formation with the latest ICL models was 5.2%. In the 
US trial,38 the rate of symptomatic and asymptomatic 
anterior subcapsular opacities was 12.6% with the V3 
model and 2.9% with the V4 model. Furthermore, the 
rate of clinically signifi cant cataract was 9.2% in the 
TABLE 2
Studies Reporting an Increase in Intraocular Pressure After 
Implantable Collamer Lens (ICL) Implantation
Study No. of Eyes No. (%) Potential Cause Management
Alfonso et al31  964  12 (1.2) High vault Temporary topical 
medication
Chun et al48  81  9 (11.1) Steroid Temporary topical 
medication
Chang & Lau11  44  1 (2.3) Steroid Temporary topical 
medication
Lackner et al26  76  1 (1.3) — Temporary topical 
medication
Rayner et al36  126  1 (0.8) High vault ICL replacement
Chang & Meau29  61  16 (26.2) Suspected pupillary block 
(1 eye), steroid (1 eye)
Temporary topical 
medication
Chung et al32  49  18 (2.0) Pigment dispersion Prolonged topical 
medication (1 eye)
Sanders et al2  526  21 (4.0) Pupillary block Additional iridotomies
Smallman et al49 Case report 1 Pupillary block Additional iridotomies
Vetter et al50 Case report 1 Pupillary block ICL explantation 
Bylsma et al51 Case report 1 Pupillary block Additional iridotomies
Sánchez- Galeana et al52 Case report 1 Pigment dispersion ICL explantation 
Park et al53 Case report 2 Pigment dispersion ICL explantation 
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V3 group and 0.8% in the V4 group. These results have 
also been confi rmed by other authors,26,59  which sup-
port the lower occurrence derived from this review 
compared to the earlier review by Chen et al.23 
Overall, the occurrence of early onset cataract seems 
to have decreased in recent years, which may be at-
tributed to the changes in lens design of the V4 model, 
compared to the less vaulted anterior models, and 
surgical-related factors such as the surgeon’s learning 
curve and skill. Despite this refi nement in lens design, 
the selection of lens parameters and the execution of 
surgical maneuvers are still critical for long-term suc-
cess as they defi ne the physical position of the lens 
in the posterior chamber. An underestimation in the 
selection of the ICL diameter is frequently associated 
with poor vault (,250 µm), thereby increasing the risk 
of cataract formation, whereas an oversized ICL may 
result in excessive vault (.750 µm), thereby increasing 
the risk of angle-closure, pupillary block glaucoma, or 
pigment dispersion glaucoma. 
Because the haptics of the ICL rest in the ciliary sul-
cus, the overall size of the ICL depends on the cili-
ary sulcus diameter. The ideal approach to selecting 
the appropriate size ICL would be to directly measure 
the sulcus-to-sulcus length. Before the development of 
high-resolution ultrasound biomicroscopy, no system 
allowed determination of the internal diameter of the 
ciliary sulcus. This evaluation relied on white-to-white 
measurement. The ICL’s diameter is oversized 0.5 to 
1.0 mm from the white-to-white measurement in myo-
pic eyes, and is the same length or oversized 0.5 mm in 
hyperopic eyes, and the amount of ideal postoperative 
vault must create a clearance space over the whole an-
terior crystalline lens surface and was recommended 
to be equal to 1.0 to 1.5 times the central corneal thick-
nesses on slit-lamp examination, which corresponds 
to an approximate value between 400 and 600 µm.66 
However, regardless of the accuracy of the white-to-
white measurement, recent studies demonstrate that 
there is no accurate anatomical relationship between 
external measurements and internal dimensions.67-69 
Therefore, white-to-white distance alone may not pre-
dict angle or sulcus size, and size mismatches can oc-
cur, making this method unlikely to predict accurate 
vault values.70 Moreover, it has been reported that ICL 
length determined by high-resolution ultrasound bio-
microscopy rendered signifi cantly more ideal ICL vault 
than the conventional white-to-white method.71 In ad-
dition, changes made in size nomogram also proved to 
provide a more satisfactory vault.29
Other non-surgeon–dependent factors, such as high 
myopia and consequently higher ICL power, have also 
been related to earlier cataract development; the poten-
tial role of the thicker periphery in high-power lenses 
has been associated as well. 
The anterior segment (including anterior and pos-
terior chambers) is a dynamic rather than static space. 
Factors such as accommodation and aging or dynamic 
interactions between the ICL and crystalline lens and 
with the back surface of the iris during accommodation 
or pupillary dynamics13,72,73 affect the space available 
between the posterior cornea and anterior crystalline 
lens surface. Considering the relatively early patient 
age for the implantation of these lenses, PIOLs such 
as the ICL are subjected to these variations. Yan et al67 
have shown that the crystalline lens rises on average 
TABLE 3
Studies Reporting the Percentage of Endothelial Cell Loss After 
Implantable Collamer Lens (ICL) Implantation
Study No. of Eyes ICL Type (%) Endothelial Cell Loss (%) (Time)
Pesando et al7  50 ICH 4.7 (10 y)
Kamiya et al33  56 ICM 2.0 (1 y); 3.7 (5 y)
Chung et al32  49 ICM 9.9 (2 y)
Lackner et al26  76 ICM 8.3 (1 y); 6.4 (3 y)
Pineda-Fernández et al59  12 ICM 4.9 (1 y); 6.1 (3 y)
Dejaco-Ruhswurm et al60  8 ICM 5.5 (1 y); 12.3 (4 y)
Edelhauser et al61  212 ICM 8.9 (1 y); 9.5 (4 y)
Chang & Lau11  44 TICL 11.0 (1 y)
Kamiya et al37  56 TICL 2.9 (1 y)
Total  551 7.17; 7.51
ICH = ICL for hyperopia, ICM = ICL for myopia, TICL = toric ICL for astigmatism
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28 µm per diopter of accommodation, which is associ-
ated to a decrease in anterior chamber depth of 24 µm 
per diopter. As the eye ages, accommodation plays a 
less signifi cant role, but other changes occurring in the 
crystalline lens that might compromise the amount of 
safe space from the ICL must be considered. Indeed, 
it is well known that the anterior chamber decreases 
in the aging eye.74 Such decrease in anterior chamber 
depth is likely to be induced by the thickening of the 
aging crystalline lens at an average rate of 24 µm/year 
as reported by Atchison et al.75 This might help coun-
terbalance the slight decrease in vault several years after 
surgery.31,35,76,77 Finally, the anatomic confi guration 
and age-related changes of the ciliary muscle must be 
taken into account.78 The age-related increase in antero-
posterior thickness of the ciliary muscle in phakic pa-
tients54 might somewhat affect the positioning of the 
ICL over time. Recent information about the biometry 
of the anterior segment of the eye and its changes with 
age and accommodation should help improve these 
outcomes even further. Overall, the improvement of 
new anterior segment imaging should improve the ICL 
selection nomogram, thus increasing the safety of the 
procedure. Although ICL implantation can be consid-
ered a safe and effective method for the surgical cor-
rection of moderate to high refractive errors, follow-up 
studies are needed to establish the long-term safety of 
these posterior PIOLs.
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